The National Health Council (NHC) appreciates this opportunity to provide feedback on Congressional efforts to address drug pricing including H.R. 3, the Lower Drug Costs Now Act, and S. 2543, […]
Letters + Comments
Letter to Representatives DeGette & Upton on the “Cures 2.0” Initiative
Dear Representative DeGette and Representative Upton: The National Health Council (NHC) appreciates this opportunity to provide feedback on your work to help advance medical research and foster medical innovations in […]
2020 Proposed Changes to Institute for Clinical and Economic Review’s (ICER) Framework
The National Health Council (NHC) is pleased to provide comments on the Institute for Clinical and Economic Review’s (ICER) solicitation for comments on the proposed 2020 Value Assessment Framework update. […]
2020 Revisions to Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment Policies
The National Health Council appreciates the opportunity to comment on the Centers for Medicare & Medicaid Services’ proposed rule revising payment policies under the Medicare Physician Fee Schedule (the Proposed […]
Proposed Changes to the Medicare Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System
The National Health Council appreciates the opportunity to comment on the proposed changes to the Medicare Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System (the Proposed Rule). Our […]
Value Assessment Methods for Single or Short-Term Transformative Therapies (SSTs)
The National Health Council (NHC) is pleased to provide comments on the Institute for Clinical and Economic Review’s (ICER) solicitation for feedback on the, “Value Assessment Methods for Single or […]
Centers for Medicare & Medicaid Services’ (CMS’) Request for Information: Reducing Administrative Burden to Put Patients over Paperwork
The National Health Council (NHC) appreciates the opportunity to respond to the Centers for Medicare & Medicaid Services’ (CMS’) Request for Information entitled “Reducing Administrative Burden to Put Patients over […]
Food and Drug Administration’s (FDA’s) Draft Guidance on Enhancing the Diversity of Clinical Trial Populations
The National Health Council (NHC) appreciates the opportunity to provide comments on the Food and Drug Administration’s (FDA’s) draft guidance on Enhancing the Diversity of Clinical Trial Populations. While industry […]
NHC’s Support of a Cap on Out-of-Pocket Costs for Medicare Part D
Dear Chairman Grassley and Ranking Member Wyden: As the Senate Finance Committee is crafting legislation related to prescription drug and other health care costs, the National Health Council (NHC) writes […]
Institute for Clinical and Economic Review’s (ICER) Solicitation for Feedback on the 2020 Value Assessment Framework
The National Health Council (NHC) is pleased to provide comments on the Institute for Clinical and Economic Review’s (ICER) solicitation for feedback on the 2020 Value Assessment Framework. Founded in […]